Alnylam Pharmaceuticals, Inc., 10% Owner at Regulus Therapeutics Inc. ("RGLS"), sold 7,600 shares at $6.66 ($52K) on 2014-08-07, disclosed to the SEC on 2014-08-08.
Scheduled sale ($52k) by 10% Owner under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $7.08 | 3,150 | $22K | 42.7% |
| 2 | $6.66 | 2,600 | $17K | 33.2% |
| 3 | $6.80 | 1,850 | $13K | 24.1% |
| Total | $6.87 avg | 7,600 | $52K | 100% |
| Filing → |
| RGLS | SELL | 2014-10-24 | $1.6M | — | Filing → |
| RGLS | SELL | 2014-10-17 | $81K | — | Filing → |
| RGLS | SELL | 2014-10-10 | $66K | — | Filing → |